Archivo de informes
Todos los análisis
Página 10 de 52 · 1235 informes
36/100
27Buffett
Kinross Gold: A Gold-Levered Cash Machine in Transition, but at 23.50 USD the Unresolved Cost Gap Leaves No Margin of Safety
Kinross Gold is a senior gold producer with mines in the United States, Brazil, Chile and Mauritania, plus the Great Bear development project in Ontario. Second-quarter 2026 attributable free cash flow of 726.8 million dollars came mainly from a realized gold price of 4,483 dollars an ounce rather than from cost control, as attributable AISC rose to 1,821 dollars against reaffirmed full-year guidance of about 1,730. Rating Hold: net cash near 1.92 billion dollars and a real Ontario growth option are offset by gold dependence and an unproven second-half cost bridge, and at 23.50 USD the shares sit inside the acceptable-hold band with no margin of safety.
38/100
Parsons: A Record 35% Crash Repriced Earnings Quality, and at 40.32 USD the Price Is Interesting but Not Yet Safe
Parsons is a US federal technology and critical infrastructure contractor, pairing defense and intelligence work for the US government with transportation and infrastructure programs concentrated in the Middle East. Second-quarter 2026 revenue was flat at $1.576bn and the reported adjusted EBITDA margin fell to 2.7%, normalizing to 10.1% only after $77.5m of remote-program losses and a $40.9m legacy JV charge, while management cut midpoint full-year adjusted EBITDA guidance by 17.8%. Rating Watch: the franchises and the $9.26bn backlog are real, but after a record 35.0% single-day crash the $40.32 price still sits above the $31 to $34 ideal buy zone.
58/100
TeraWulf: Lake Mariner Is a Real Scarce-Power Campus, but at 15.09 USD the Price Already Assumes Substantial Execution Success
TeraWulf is a former bitcoin miner turning Lake Mariner, a retired coal-plant site in Western New York, into a contracted AI/HPC campus leased to Fluidstack with Google credit support. HPC leasing became the majority of revenue for the first time in the March 2026 quarter at 21.0 million dollars, but the 6.7 billion dollar headline contract value compresses hard against build costs of 8 to 10 million dollars per MW, 3.2 billion dollars of Lake Mariner secured notes and roughly 819 million reserved shares. Rating Watch: the campus and the contracts are real, yet at 15.09 USD the price already sits above the 9 USD value implied by the conservative scenario.
46/100
82Buffett
BAE Systems: The Portfolio Moat Is Genuine, but at 20.27 GBP the Rerating Has Already Outrun Earnings Growth
BAE Systems is a UK-listed defence prime with a more American revenue base than the label suggests, spanning combat air, electronic systems, submarines, land systems and cyber. FY2025 sales reached 30.7 billion pounds with underlying EBIT of 3.322 billion and a 10.8% group return on sales, yet the 83.6 billion headline backlog shrinks to 63.1 billion on the stricter IFRS measure and segment margins run from 15.4% in Electronic Systems down to 6.7% in Maritime. Rating Hold: the breadth and the demand cycle are genuine, but at 20.27 pounds the stock trades on about 24.5 times forward earnings with a 3.6% free cash flow yield against 5.0% gilts, leaving the ideal buy zone at 12.00 to 14.50 pounds.
55/100
AMD: The Rack-Scale AI Story Got More Credible, but 495 USD Already Prices Durable Number-Two Platform Status
AMD is a fabless designer whose profit engine has shifted to data-center CPUs and AI accelerators, and it is now trying to become the open, rack-scale second source for frontier AI infrastructure. Helios, the disclosed up-to-6-gigawatt Meta framework and named Microsoft, Oracle and OpenAI engagements make that ambition far more credible than it was in May, yet 2025 revenue of 34.6 billion USD and net income of 4.335 billion USD leave the stock at roughly 23 times sales and 186 times trailing earnings. Rating Avoid: the platform transition is real, but at 494.95 USD the margin of safety is zero and the ideal buy zone sits at 175 to 208 USD.
48/100
57Buffett
Saint-Gobain: A Higher Margin Floor Is Proven, but at 74.16 EUR the Price Sits Above the 64 EUR Conservative Value
Saint-Gobain is a global light-construction group that pairs local building-material platforms with a fast-growing construction-chemicals engine. 2025 delivered 46.5 billion euros of sales, a 15.5% EBITDA margin and 3.75 billion euros of free cash flow, yet Q1 2026 sales fell 2.3% like-for-like with North America down 11.3%. Rating Hold: the transformation is proven and the shares trade near 12.8x earnings against Sika at 24x, but at 74.16 EUR the price sits above the 64 EUR conservative value and the classical margin of safety is missing.
62/100
44Buffett
Amazon: AWS Demand and AI Commitments Are Real, but 230.86 USD Still Asks Investors to Fund a 200 Billion USD Capex Cycle Without a Margin of Safety
Amazon is a compound platform whose commerce and logistics network feeds a high-margin advertising and subscription layer, while AWS supplies the profit. 2025 revenue reached 716.9 billion USD, yet trailing free cash flow collapsed to 1.2 billion by Q1 2026 as capex climbed toward a projected 200 billion USD for the year, even as AWS reaccelerated to 28% growth. Rating Hold: the AI demand evidence is now partly contracted and real, but at 230.86 USD the stock sits about 28% above the conservative fair value of 180 USD with no margin of safety.
51/100
Fujimi: The Hidden Champion of CMP and Silicon-Wafer Polishing Materials, but 3,680 Yen Already Prepays a Good Deal of the Next Few Years
Fujimi is a Japanese precision-abrasives maker whose profit core is front-end CMP slurry and silicon-wafer polishing materials, which together approach 80% of revenue. In the fiscal year ended March 2026 it produced 69.404 billion JPY of revenue and 13.826 billion JPY of operating income, with operating margin back at 19.9%, yet the company's own estimate puts its share across all CMP steps at just 13%, with the very high shares concentrated in silicon-wafer polishing. Rating Watch: the business quality and the FEOL moat are real, but a trailing P/E near 30x already prepays the growth and leaves a thin margin of safety.
58/100
Wix.com: The Partner Channel Is Where AI Shows Up First, and 58.55 USD Prices a Permanent Erosion the Disclosed Evidence Does Not Yet Support
Wix runs a cloud platform for website creation, commerce and small-business software, monetized through recurring subscriptions plus attached payments and business tools. 2025 revenue reached 1.99 billion USD and Q1 2026 bookings still grew 15%, but non-GAAP operating margin fell to 5% from 21% and the June 8 6-K conceded a sharper-than-expected slowdown in the Partners channel. Rating Cautious Buy: at 58.55 USD the market is pricing a permanent AI-driven erosion that the disclosed evidence does not yet support.
67/100
91Buffett
Microsoft: Azure Demand Is Real and the Moat Is Intact, but 393 USD Already Prices a Clean Conversion of the 190 Billion USD Capex Wave
Microsoft is a cash-rich enterprise software and cloud platform whose profit pool sits in Productivity and Intelligent Cloud, and it is now funding an unprecedented AI infrastructure build. Fiscal 2025 produced 281.7 billion USD of revenue and 136.2 billion USD of operating cash flow, yet calendar-2026 capex is guided at roughly 190 billion USD and trailing free cash flow falls from 72.9 billion to 41.7 billion USD once finance leases are counted. Rating Hold: the moat and the Azure demand are real, but 393 USD already assumes that capex wave converts cleanly into owner earnings.
66/100
81Buffett
NVIDIA: Demand Has Broadened Beyond the Hyperscalers, but Its Funding Base Has Not, and 197 USD Already Prices Continued Excellence
NVIDIA sells accelerated-computing platforms rather than loose chips, pairing GPUs and rack-scale systems with high-speed networking, a growing CPU line and the CUDA software estate. Fiscal 2026 revenue reached 215.9 billion USD with 193.7 billion USD from Data Center, yet three direct customers accounted for 21%, 17% and 16% of Q1 FY2027 revenue and the AI buildout is leaning harder on external financing than headline growth suggests. Rating Hold: at 197.01 USD the stock is credible to own but offers no margin of safety, with the ideal buy zone at 100 to 110 USD.
49/100
Zymeworks: The Molecule Is Proven, the Allocator Is Not
Zymeworks is a biotech licensor rebuilding itself into a cash-flow aggregator: zanidatamab royalties and milestones collected through Jazz and BeOne, plus a pending Theravance acquisition that would add YUPELRI profit-share economics. The engine is real but still thin, and both of its best streams are already pledged: 30% of Ziihera royalties back a $250 million Royalty Pharma note, and 75% of YUPELRI profit share would service a $350 million OMERS note. Rating Hold: at $22.61 the shares sit inside the acceptable-hold band but above the conservative case, so investors are paying for the transition before the deal and the August 25, 2026 PDUFA resolve.
49/100
45Buffett
EVE Energy: Storage Now Leads the Growth and Carries the Thinnest Margin, and Capex Still Outruns the Cash It Converts
EVE Energy is a Chinese lithium-battery maker whose center of gravity has moved to grid and utility storage, already 39.8% of 2025 revenue and the largest quarterly shipment line by Q1 2026. Annual operating cash flow of CNY 7.492bn converts at about 1.81 times net profit, but CNY 10.45bn of fixed-asset spending keeps free cash flow negative, and storage carries the thinnest gross margin of the three segments at 12.28%. Rating Watch: the storage position is real, yet the price already sits above the conservative value and the ideal buy zone is 38 to 45 CNY.
48/100
82Buffett
T&S Communications: A Real Upstream Bottleneck, Priced as if Scarcity Economics Were Permanent
T&S Communications is an upstream optical-component supplier whose active optical components, led by 1.6T optical engines, reached 58.1% of revenue in 2025 as revenue grew 58.8% to CNY 5.16 billion with about CNY 2.02 billion of attributable net profit. The business quality is real but so is the concentration: the top five customers were 90.6% of revenue and the largest alone 63.9%. Rating Avoid: at CNY 209.19 and roughly 110 times static earnings, even the report's optimistic scenario of CNY 165 per share sits below the current price.
28/100
DENTSPLY SIRONA: A Real Dental Incumbent, but the Repricing Is Permanent and 13.02 USD Already Prices Base Value
DENTSPLY SIRONA is a broad, diversified dental supplier spanning consumables and endodontics, implants, imaging and chairside CAD/CAM equipment. Sales of 3.68 billion USD in 2025 produced free cash flow of only 104 million USD, and market value has fallen from about 11.11 billion USD at end-2016 to roughly 2.55 billion USD. Rating Watch: the discount is a permanent repricing of business quality, governance trust and category relevance rather than a cyclical dip, so at 13.02 USD the stock already trades near base value and the ideal buy zone is 7 to 9 USD.
53/100
Innovent Biologics: The China Platform Is Real, but the Price Already Pre-Pays the Obesity Curve
Innovent Biologics is a China biopharma with 18 approved products, an oncology commercial base that produced RMB11.93 billion of 2025 product revenue, and a new obesity franchise built on mazdutide. 2025 brought the first full-year profit of RMB813.6 million, but headline operating cash flow of RMB10.0 billion was flattered by a RMB7.64 billion contract-liability inflow tied to Takeda's upfront. Rating Hold: at HK$89.35 and roughly 10 times trailing sales, the price already pre-pays much of the obesity and licensing upside before the economics are proven.
52/100
65Buffett
Oracle Corporation
Oracle is an enterprise software and cloud infrastructure vendor whose database and applications cash engine is now funding a massive AI data-center build-out. Fiscal 2026 revenue reached 67.4 billion USD and remaining performance obligations hit 638 billion USD, but capex of 55.7 billion USD drove free cash flow to negative 23.7 billion USD, and S&P cut the credit rating to BBB- in July. Rating Hold: the 34% fall from the previous report's 181 USD reference point has absorbed much of the financing anxiety, but at 119.90 USD there is still no meaningful margin of safety for new money.
49/100
Tesla: The Franchise Is Real, but $900 Billion of the Market Cap Rests on Robotaxi Economics No One Has Disclosed
Tesla is an integrated EV and battery-storage manufacturer whose trailing-twelve-month revenue now exceeds $100 billion, and it is redirecting that industrial base to fund robotaxis, AI infrastructure and humanoid robots. Q2 2026 revenue rose 26% to $28.236 billion while operating income fell 57% to $398 million, operating margin dropped to 1.4%, capex jumped 142% to $5.789 billion and free cash flow swung to negative $1.092 billion, with 2026 capex now guided above $25 billion. Rating Watch: the visible auto, energy and charging businesses are worth roughly $140 to $190 billion against a $1.095 trillion market cap, which leaves about $905 to $955 billion of the price resting on robotaxi and Optimus economics the company has not disclosed.
61/100
Figma: The Platform Role Is Real, but Dilution and the Last Unlock Leave No Margin of Safety
Figma is a browser-native collaborative design platform that monetizes Full, Dev, and Collab seats across Professional, Organization, and Enterprise plans, with governance add-ons and, since March 2026, paid AI credits layered on top. Q1 2026 revenue rose 46% to $333.4 million and net dollar retention reached 139%, yet GAAP gross margin fell to 79% from 91% a year earlier as AI hosting costs jumped, and roughly $1.96 billion of unrecognized stock-based compensation still sits on the books. Rating Watch: the platform role looks more durable than the market's AI-obsolescence narrative implies, but dilution, margin pressure, and a final 77.7 million-share lock-up release leave no margin of safety at $22.94.
35/100
JOINN Laboratories (China) Co., Ltd.
JOINN Laboratories is China's largest listed non-clinical CRO, running GLP toxicology and drug-safety studies while owning a herd of more than 20,000 research primates carried on the balance sheet at fair value. Reported earnings are now driven by that biological-asset line rather than by service margins: H1 2026 guidance puts attributable net profit at RMB 600.1 million to RMB 900.2 million on revenue of only RMB 668.6 million to RMB 739.0 million, with macaque revaluation contributing RMB 703 million to RMB 777 million while laboratory services swing between a RMB 142 million loss and a RMB 65 million profit. Rating Avoid: at CNY 49.70 the A-share trades near 75x trailing earnings and at roughly a 130% premium to its own H-share, capitalizing a cyclical accounting gain as if it were durable service profit.
43/100
82Buffett
RPM International Inc.
RPM International is a decentralized holding company built around specialty coatings, sealants and construction chemicals, selling repair, restoration and protective-coatings brands like Rust-Oleum, DAP, Tremco, and Stonhard to a $7.86 billion fiscal 2026 revenue base. A multi-year MAP 2025 operating program has held gross margin flat through an inflationary stretch and lifted cash conversion, but at roughly 20.6 times trailing earnings the stock already prices in most of that self-help progress just as fiscal 2027 opens with fresh raw-material and tariff inflation. Rating Hold: a genuinely improving quality business, but with a thin margin of safety until the next cost cycle proves manageable.
31/100
Jianghua Micro: A Real but Mixed Wet-Chemicals Business Priced Like a Pure Semiconductor-Materials Platform
Jiangyin Jianghua Microelectronics is a wet electronic chemicals maker selling ultra-pure reagents and photoresist-supporting chemicals across semiconductor, display, and solar customers, with semiconductor now the largest end market at about CNY 711 million of 2025 revenue. The stock trades as if this were already a pure semiconductor-materials platform, but 2025 revenue rose only 12.3% and net profit 6.3% while the shares changed hands around 116x trailing earnings, well above stronger or more focused domestic peers Shanghai Sinyang (83x), Anji Micro (71x), and Greenda (63x). Research rating Avoid: real domestic-substitution progress and improving mix are being capitalized at a multiple that already assumes years of successful fab penetration the company has not yet delivered.
43/100
Envista Holdings Corporation
Envista Holdings is a diversified dental-products company built from Danaher's former dental segment, selling implants, orthodontics, imaging, and consumables across a $2.72 billion revenue base. A 2023-2024 stretch of guidance cuts and a $1.15 billion goodwill impairment gave way to a broad recovery: four straight quarters of positive core growth and expanding margins, with 2026 guidance reaffirmed, but the current price near $26 already credits much of that repair, leaving only a thin owner-earnings yield above risk-free Treasury bonds. Rating Hold: genuine operational improvement, but limited margin of safety until the recovery proves durable through tougher comparisons.
42/100
Shanghai Sinyang Semiconductor Materials: A Real Domestic-Substitution Winner, but Today's Price Already Discounts Years of Fab Penetration
Shanghai Sinyang is a China A-share semiconductor materials supplier that has pivoted from a legacy specialty-coatings business into a domestic-substitution winner across electroplating, cleaning, etching, photoresist, and CMP wet-process chemicals for wafer fabs. 2025 semiconductor revenue reached CNY 1.517 billion, up 46.5% year over year, and the company now describes itself as a baseline-qualified supplier on 66 domestic 12-inch and 25 8-inch production lines, with net profit up 71% and operating cash flow more than doubling, though the stock already trades around 90 times trailing earnings against a CNY 38-43 fair-value range. Rating Hold: a real domestic-substitution winner, but today's price already discounts several more years of successful fab penetration and margin retention.